Skip to main content
Editorial
Can real-world evidence save pharma US$1 billion per year? A framework for an integrated evidence generation strategy
- Melvin (Skip) Olson
pp79–82
Published Online:27 November 2019
Research Article
Biomedical conferences’ author instructions rarely mention guidelines for reporting abstracts of trials and systematic reviews
- Lenko Saric,
- Svjetlana Dosenovic,
- Jakov Mihanovic, and
- Livia Puljak
pp83–91
Published Online:17 January 2020
Crizotinib versus chemotherapy: a real-world cost–effectiveness study in China
- Meijuan Huang,
- Yuke Tian,
- Mingmin He,
- Juan Liu,
- Li Ren,
- Youling Gong,
- Feng Peng,
- Yongsheng Wang,
- Zhenyu Ding,
- Jin Wang,
- Jiang Zhu,
- Yong Xu,
- Yongmei Liu,
- Lanting Li, and
- You Lu
pp93–102
Published Online:21 January 2020
Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer
- Ian Chau,
- Dieter Ayers,
- Sarah Goring,
- Shannon Cope,
- Beata Korytowsky, and
- Pranav Abraham
pp103–114
Published Online:24 December 2019
Comparative effectiveness of catheter ablation devices in the treatment of atrial fibrillation: a network meta-analysis
- Dhiraj Gupta,
- Tom De Potter,
- Tim Disher,
- Kiefer Eaton,
- Laura Goldstein,
- Leena Patel,
- Daniel Grima,
- Maria Velleca, and
- Graça Costa
pp115–126
Published Online:8 January 2020
The 1-year economic burden of community-acquired pneumonia (CAP) initially managed in the outpatient setting in the USA
- Victoria Divino,
- Jennifer Schranz,
- Maureen Early,
- Hemal Shah,
- Miao Jiang, and
- Mitch DeKoven
pp127–140
Published Online:16 December 2019
Review
Experimental design issues in choice-based conjoint applied to patient choice in healthcare
- Pallavi Chitturi and
- Alexandra Carides
pp141–147
Published Online:17 January 2020